Business Context and Reporting Period
Pacific Biosciences of California, Inc. (PACB) filed a Current Report on Form 8-K dated January 24, 2023, with the report signed on January 27, 2023. The filing discloses the entry into a material definitive agreement regarding a public offering of common stock.
Key Financial Metrics and Transaction Details
- Shares Issued: 17,500,000 shares of Common Stock.
- Option Shares: Underwriters exercised their option in full to purchase an additional 2,625,000 shares.
- Total Shares Sold: 20,125,000 shares.
- Public Offering Price: $10.00 per share.
- Net Proceeds: Approximately $189.2 million (after underwriting discounts and estimated offering expenses).
- Underwriters: Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and Cowen and Company, LLC.
Material Changes and Transaction Status
The offering closed on January 27, 2023. This transaction represents a significant capital raise for the Company. The filing does not provide comparative financial metrics (revenue, profit, cash flow) for the current period versus prior periods, as this is a transactional report rather than a periodic financial statement.
Management Commentary, Risks, and Contingencies
- Lock-Up Agreements: Certain officers and directors have entered into lock-up arrangements prohibiting the sale or transfer of securities for a 60-day period, subject to exceptions.
- Indemnification: The Company agreed to indemnify the Underwriters against certain liabilities under the Underwriting Agreement.
- Legal Opinions: A legal opinion regarding the legality of the Common Stock sold was filed as an exhibit.
- Emerging Growth Company: The registrant is identified as an emerging growth company.
Investor Verification Checklist
- Verify the final closing date of the offering (January 27, 2023) and the full exercise of the 30-day option.
- Confirm the exact net proceeds of $189.2 million against the final prospectus supplement.
- Review the specific terms of the 60-day lock-up agreements for officers and directors.
- Check subsequent filings for the impact of this capital raise on the Company's cash position and liquidity.